Spotlight On... SRI pairs with Stanford on discovery project; Aptuit invests in early R&D; and much more...

SRI International's in-house CRO has teamed up with Stanford University to find some early-stage treatments for cancer and push them through preclinical development. Under what has been dubbed the SRI Biosciences-Stanford Drug Discovery and Development Program, the two institutions plan to pool their resources and expertise in hopes of hitting on first-in-class therapies for multiple forms of cancer. More

> Aptuit is investing $16 million in infrastructure and planning to hire about 90 scientists in Europe as it works to expand its share of the market for drug discovery services. News

> Evotec notched a milestone in its endometriosis-focused partnership with Bayer, advancing two projects toward clinical development. Item